Christa Thorpe
About Christa Thorpe
Christa Thorpe is an Executive Territory Business Manager and Melanoma Institutional Tumor Specialist at Bristol-Myers Squibb in New Jersey, United States.
Company
Christa Thorpe is currently working at Bristol-Myers Squibb, a global biopharmaceutical company. She has been an integral part of the organization for over 25 years, beginning her tenure in September 1995. Bristol-Myers Squibb is known for its innovative work in the healthcare sector, focusing on discovering, developing, and delivering revolutionary medicines. Christa's role within the company aligns with its mission to combat serious diseases.
Title
Christa Thorpe serves as the Executive Territory Business Manager and Melanoma Institutional Tumor Specialist at Bristol-Myers Squibb. Her responsibilities include overseeing territory business operations and specializing in melanoma treatment and institutional tumor management, ensuring the company delivers effective therapeutic solutions.
Education and Expertise
Christa Thorpe holds a Bachelor of Science in Nursing from the University of Toronto. She earned her degree after four years of study from 1991 to 1995. Her academic background in nursing provides a solid foundation for her specialized role in melanoma treatment and institutional tumor management. Her extensive education equips her with the knowledge and skills necessary for the healthcare sector.
Background
Christa Thorpe has a background in nursing with a Bachelor of Science from the University of Toronto. She began her career at Bristol-Myers Squibb in September 1995 and has accumulated over 25 years of experience in the field. Her long-term commitment to the company highlights her dedication and expertise in the healthcare and biopharmaceutical industry.
Specialization in Melanoma Treatment
In her role, Christa Thorpe specializes in melanoma treatment and institutional tumor management. Her expertise in this specific area aligns with the advanced research and development focus of Bristol-Myers Squibb, contributing significantly to the company’s efforts in providing effective treatments for patients suffering from melanoma.